InvestorsObserver
×
News Home

Is Voyager Therapeutics Inc (VYGR) a Bad Choice in Biotechnology Tuesday?

Tuesday, March 19, 2024 01:48 PM | InvestorsObserver Analysts

Mentioned in this article

Is Voyager Therapeutics Inc (VYGR) a Bad Choice in Biotechnology Tuesday?

A rating of 81 puts Voyager Therapeutics Inc (VYGR) near the top of the Biotechnology industry according to InvestorsObserver. Voyager Therapeutics Inc's score of 81 means it scores higher than 81% of stocks in the industry. Voyager Therapeutics Inc also received an overall rating of 68, putting it above 68% of all stocks. Biotechnology is ranked 16 out of the 148 industries.

Overall Score - 68
VYGR has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on VYGR!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Voyager Therapeutics Inc Stock Today?

Voyager Therapeutics Inc (VYGR) stock is trading at $9.97 as of 1:42 PM on Tuesday, Mar 19, a gain of $0.88, or 9.67% from the previous closing price of $9.09. The stock has traded between $9.32 and $10.14 so far today. Volume today is 676,789 compared to average volume of 699,766. Click Here to get the full Stock Report for Voyager Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App